Back to News
Market Impact: 0.5
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Source: reuters.com
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
Atavistik Bio signed a development deal with Roche potentially worth nearly $2 billion, including milestone payments, to advance oral therapies for cardiovascular, kidney and metabolic diseases. The transaction validates Atavistik's drug-development platform and expands Roche's pipeline in major chronic-disease markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.68
Ticker Sentiment
ROP0.45
More News
- MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- Fox Holds Investor Calls Before Planned Bond Sale for Roku Deal